Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Nov 30;16(12):28347-76.
doi: 10.3390/ijms161226090.

MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer

Andrea Mathe  1   2 , Rodney J Scott  3   4   5 , Kelly A Avery-Kiejda  6   7
Affiliations
Review

MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer

Andrea Mathe et al. Int J Mol Sci. .

Abstract

Triple negative breast cancer (TNBC) is characterised by the lack of receptors for estrogen (ER), progesterone (PR), and human epidermal growth factor 2 (HER2). Since it cannot be treated by current endocrine therapies which target these receptors and due to its aggressive nature, it has one of the worst prognoses of all breast cancer subtypes. The only treatments remain chemo- and/or radio-therapy and surgery and because of this, novel biomarkers or treatment targets are urgently required to improve disease outcomes. MicroRNAs represent an attractive candidate for targeted therapies against TNBC, due to their natural ability to act as antisense interactors and regulators of entire gene sets involved in malignancy and their superiority over mRNA profiling to accurately classify disease. Here we review the current knowledge regarding miRNAs as biomarkers in TNBC and their potential use as therapeutic targets in this disease. Further, we review other epigenetic changes and interactions of these changes with microRNAs in this breast cancer subtype, which may lead to the discovery of new treatment targets for TNBC.

Keywords: DNA methylation; microRNA; triple negative breast cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overview of the process of epithelial-mesenchymal transition (EMT).
See this image and copyright information in PMC

References

    1. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in globocan 2012. Int. J. Cancer. 2015;136:E359–E386. doi: 10.1002/ijc.29210. - DOI - PubMed
    1. Den Hollander P., Savage M.I., Brown P.H. Targeted therapy for breast cancer prevention. Front. Oncol. 2013;3 doi: 10.3389/fonc.2013.00250. - DOI - PMC - PubMed
    1. Maxmen A. The hard facts. Nature. 2012;485:S50–S51. doi: 10.1038/485S50a. - DOI - PubMed
    1. Gucalp A., Traina T.A. Triple-negative breast cancer: Adjuvant therapeutic options. Chemother. Res. Pract. 2011;2011 doi: 10.1155/2011/696208. - DOI - PMC - PubMed
    1. Wong-Brown M.W., Meldrum C.J., Carpenter J.E., Clarke C.L., Narod S.A., Jakubowska A., Rudnicka H., Lubinski J., Scott R.J. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res. Treat. 2015;150:71–80. doi: 10.1007/s10549-015-3293-7. - DOI - PubMed

Publication types

LinkOut - more resources